In preclinical animal models, administration of IL-1β inhibitors, including IL-1 receptor antagonists (IL-1RA) or anti-IL-1β antibodies, has been shown to mitigate liver inflammation, steatosis, and fibrosis [134]. Here, IL1B is linked to digestive system neoplasm.